Abstract: Methods and systems for Resonant Raman spectroscopy are provided. Methods according to certain embodiments include irradiating a sample with a monochromatic light source at a first irradiation intensity and a second irradiation intensity, determining the intensity of one or more of the Resonant Raman scattering and fluorescence scattering at the first irradiation intensity and second irradiation intensity, calculating a rate of change of one or more of the intensity of Resonant Raman scattering and fluorescence in response to the change in irradiation intensity from the first irradiation intensity to the second irradiation intensity and comparing one or more of the rate of change in the intensity of Resonant Raman scattering and the rate of change in the intensity of fluorescence scattering with the rate of change in the irradiation intensity by the monochromatic light source to determine the Resonant Raman response of the sample.

Abstract: The present disclosure relates to compositions, methods and test devices for determining the presence of active leukocyte cells, for example, by using novel LE and/or HNE substrates in an electrochemical assay.

Abstract: This disclosure pertains to analytical instruments and related methods incorporating beam shaping optics for differentiating very bright and closely related signals over a wide range of operating conditions with an improved and uniform performance.

Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

Abstract: Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of gastrointestinal biofilm infections, and associated systemic symptoms caused by biofilms associated microorganisms within the gastrointestinal tract. Methods of identification, preparation and use of such physiologically acceptable anti-biofilm compositions are also provided.

Abstract: The present invention is concerned with a composition for repairing human skin. Specifically, the composition has a DNA repair enzyme and at least one phycobiliprotein. The DNA repair enzyme is a photolyase, and the photolyase and/or the phycobiliprotein is encapsulated by liposomes. The composition is effective in repairing damage to human skin as a result of environment daily stress, sun exposure, or premature-aging.

Abstract: A method of producing jellyfish collagen extract by combining hard water, frozen jellyfish, protease enzymes, and sodium bisulfate to form a mixture. Heating the mixture for a period of time to permit the mixture to react. The filter, concentrate, and dry the mixture.

Abstract: A Fe(II)- and Ca+2-chelated alginate/gelatin conjugate.

Abstract: Novel reagents comprising MS active, fluorescent compounds having an activated functionality for reaction with aldehydes and useful in labeling biomolecules such as glycans and methods of making the same are taught and described.

Abstract: A Ras protein degradation inducing molecule that can induce degradation of Ras proteins, and a pharmaceutical composition that contains this Ras protein degradation inducing molecule are provided. The Ras protein degradation inducing molecule is a conjugate of a Ras protein affinity molecule which has affinity to Ras proteins, and a proteolysis-inducing tag which has affinity to protease and does not inhibit proteolysis of proteins by the protease.

Abstract: A media supplement for culturing anaerobic bacteria is provided which comprises a filtrate of eilluent from a chemostat vessel in which a target bacterial ecosystem has been culnn-ed. Methods of using the supplement for culturing or isolating anaerobic microbial strains or cormmmities, particularly anaerobic bacteria from the human gut, are also provided.

Abstract: A three-dimensional fibrin engineered tissue construct is provided selected from: (i) a fibrin gel matrix comprising a combination of tissue-specific cells and at least one type of vascular cells; and (ii) a hybrid scaffold of fibrin gel and a polymeric synthetic scaffold comprising at least one type of vascular cells or a combination of tissue-specific cells and at least one type of vascular cells.

Abstract: A method and a kit are provided to produce a biological clear specimen within a short time and with a wide variety of biological specimens. The method includes the following steps: (1) treating a material to be cleared with an aqueous fixing solution containing paraformaldehyde or the like, a nonionic surfactant, an alkali, and optionally a buffering agent; (2) treating the material from step (1) or a conventionally fixed material with an aqueous clearing accelerator solution containing a nonionic surfactant and an alkali; and (3) treating the material produced in step (1) or (2) with an aqueous preservation solution containing a nonionic surfactant and a polyhydric alcohol. In each of the steps, the nonionic surfactant is present at a concentration of 1% or more. The kit includes solutions used in each of the steps of the method.

Abstract: A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.

Abstract: Compositions comprising cellulase and at least one poly alpha-1,3-glucan ether compound having a degree of substitution with an organic group of about 0.05-3.0 are disclosed. Such compositions can be dry or aqueous, the latter of which can have a viscosity of at least about 10 cPs. The disclosed composition can be in the form of a personal care product, household product, or industrial product, for example. Also disclosed are a method for preparing an aqueous composition comprising cellulase and a poly alpha-1,3-glucan ether compound, and a method of treating a material such as fabric by contacting it with this aqueous composition.

Abstract: Methods and compositions for improved clinical outcomes for trauma patients receiving whole blood transfusion. Methods and compositions for improved clinical outcomes for blood transfusions for cancer patients are also provided.

Abstract: A p53 degradation inducing molecule which can induce degradation of p53 proteins or p53 composites, and a pharmaceutical composition containing said p53 degradation inducing molecule are provided. This p53 degradation inducing molecule is a conjugate of a p53 affinity molecule which has affinity for p53 proteins or p53 composites, and a proteolysis induction tag which has affinity for protease and which does not inhibit proteolysis of proteins by protease.

Abstract: A saccharification reaction mixture, a saccharification enzyme composition, and a saccharide production method are aimed to enhance saccharization rate by use of an enzyme in a simple step as well as a method for producing ethanol from a saccharide. The saccharification reaction mixture can saccharify at least one of cellulose and hemicellulose and contains at least one of cellulose and hemicellulose, a saccharification enzyme, silica or a silica-containing substance, and at least one compound (A) selected from the group made of thiourea, a thiourea derivative, an isothiourea derivative, and a salt of any of these.

Abstract: The present invention relates to an exopolysaccharide derived from Pseudoalteromonas sp. strain CY01 (KCTC 12867BP) which is a novel strain living in the polar regions, and to a composition for cryoprotection of cells, which contains the exopolysaccharide. The exopolysaccharide of the present invention has an excellent ability to cryoprotect cells, and shows no cytotoxicity. Thus, the inventive exopolysaccharide can substitute for conventional cryoprotective agents that show cytotoxicity when used at high concentrations.

Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.